2-Bromo-4'-chloroacetophenone structure
|
Common Name | 2-Bromo-4'-chloroacetophenone | ||
|---|---|---|---|---|
| CAS Number | 536-38-9 | Molecular Weight | 233.490 | |
| Density | 1.6±0.1 g/cm3 | Boiling Point | 289.7±15.0 °C at 760 mmHg | |
| Molecular Formula | C8H6BrClO | Melting Point | 95-99ºC | |
| MSDS | Chinese USA | Flash Point | 129.0±20.4 °C | |
| Symbol |
GHS05 |
Signal Word | Danger | |
| Name | 2-Bromo-4’-chloroacetophenone |
|---|---|
| Synonym | More Synonyms |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 289.7±15.0 °C at 760 mmHg |
| Melting Point | 95-99ºC |
| Molecular Formula | C8H6BrClO |
| Molecular Weight | 233.490 |
| Flash Point | 129.0±20.4 °C |
| Exact Mass | 231.929047 |
| PSA | 17.07000 |
| LogP | 2.88 |
| Vapour Pressure | 0.0±0.6 mmHg at 25°C |
| Index of Refraction | 1.584 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS05 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H314 |
| Precautionary Statements | P280-P305 + P351 + P338-P310 |
| Personal Protective Equipment | Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| Hazard Codes | C:Corrosive; |
| Risk Phrases | R22;R34 |
| Safety Phrases | S26-S36/37/39-S45 |
| RIDADR | UN 3261 8/PG 2 |
| WGK Germany | 2 |
| RTECS | AM5978800 |
| Packaging Group | III |
| HS Code | 2914399090 |
| Precursor 9 | |
|---|---|
| DownStream 10 | |
| HS Code | 2914399090 |
|---|---|
| Summary | 2914399090. other aromatic ketones without other oxygen function. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:5.5%. General tariff:30.0% |
|
Design, synthesis and structure-activity relationship studies of novel and diverse cyclooxygenase-2 inhibitors as anti-inflammatory drugs.
J. Enzyme Inhib. Med. Chem. 29(6) , 846-67, (2014) Because of the pivotal role of cyclooxygenase (COX) in the inflammatory processes, non-steroidal anti-inflammatory drugs (NSAIDs) that suppress COX activities have been used clinically for the treatme... |
|
|
Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds.
J. Med. Chem. 54 , 4042-56, (2011) Development of kinase-targeted therapies for central nervous system (CNS) diseases is a great challenge. Glycogen synthase kinase 3 (GSK-3) offers a great potential for severe CNS unmet diseases, bein... |
| α-Bromo-p-chloroacetophenone |
| MFCD00000625 |
| Ethanone, 2-bromo-1-(4-chlorophenyl)- |
| ω-Bromo-4-chloroacetophenone |
| 2-Bromo-4‘-chloroacetophenone |
| 2-Bromo-4'-chloroacetophenone |
| α-Bromo-4-chloroacetophenone |
| 4'-Chloro-2-Bromoacetophenone |
| 4-Chlorophenacyl Bromide |
| EINECS 208-631-5 |
| 2-Bromo-1-(4-chlorophenyl)ethanone |
| Ethanone, 2-bromo-1- (4-chlorophenyl)- |
| α-Bromo-4'-chloroacetophenone |
| 2-bromo-1-(4-chlorophenyl)ethan-1-one |